Ocular Therapeutix, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 10, 2027The maintenance fee for Sustained Release Biodegradable Intracanalicular Inserts Comprising a Hydrogel and Cyclosporine (US 11,779,536) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 23, 2026
- Oct 13 US 12,758,490 Hydrogel Implants for Lowering Intraocular Pressure
- Oct 6 US 12,751,859 Intracanalicular Depot Inserter Device
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,559,429 | Punctal Plug and Bioadhesives In force · High confidence | In force | High confidence | |
| US 12,150,896 | Punctal Plug and Bioadhesives In force · High confidence | In force | High confidence | |
| US 12,310,890 | Punctal Plug and Bioadhesives In force · High confidence | In force | High confidence | |
| US 11,458,041 | Punctal Plug and Bioadhesives In force · High confidence | In force | High confidence | |
| US 12,758,490 | Hydrogel Implants for Lowering Intraocular Pressure In force · Medium confidence | In force | Medium confidence | |
| US 11,622,935 | Methods of Treating Ocular Diseases Using Polyalkylene Glycol Intracameral Implants with Polyactide Travoprost Particles In force · Medium confidence | In force | Medium confidence | |
| US 12,329,853 | Compositions and Methods for Treating Ocular Diseases In force · Medium confidence | In force | Medium confidence | |
| US 11,439,592 | Ocular Implant Containing a Tyrosine Kinase Inhibitor In force · Medium confidence | In force | Medium confidence | |
| US 11,534,396 | Methods of Treatment with an Ocular Implant Containing a Tyrosine Kinase Inhibitor In force · Medium confidence | In force | Medium confidence | |
| US 12,144,889 | Methods of Treating Allergic Conjunctivitis In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
15 pending · 6 abandoned